



Texas Radiotherapy Celebrates 200th Use of Barrigel [™] during Radiation Treatments

FORT WORTH--Texas Radiotherapy, a leading radiation oncology practice in Fort Worth, Texas announces their 200th use of Barrigel for prostate cancer treatment. Barrigel protects healthy tissue from unwanted radiation exposure during prostate cancer radiation treatment.

Dr. Matthew Cavey, Texas Radiotherapy's radiation oncologist, and founder of Texas Radiotherapy, stated, "We are pleased to have reached this milestone with Barrigel. Our entire team at Texas Radiotherapy incorporates the newest and proven radiation treatments to improve our patients' outcomes and care, and Barrigel is one of the treatments that helps us reach our goal of exceptional patient care."

Barrigel Spacing Consultant, Jason Severn, added, "Dr. Cavey and his team are in an elite group of radiation oncologists that have used Barrigel for 200 applications or more." Severn continued, "In a randomized, clinical trial, 98.5% of patients, who received Barrigel, as part of their radiation treatment therapy, had a significant reduction of radiation to the rectum." (Source: Mariados NF, Orio PF, Schiffman Z, et al. Hyaluronic acid spacer for hypofractionated prostate radiation therapy: a randomized clinical trial. *JAMA Oncol.* 2023; e1-e8.)

Texas Radiotherapy is a radiation oncology center focused on providing every patient with a personal, individualized treatment plan. Texas Radiotherapy is in Fort Worth at Texas Health Harris Methodist Hospital. To learn more about Dr. Cavey and his team, visit www.TexasRadiotherapy.com.

Barrigel is manufactured by Palette Life Sciences by Q-Med, AB, a subsidiary of Galderma AB. Visit www.Barrigel.com to learn more.

Media: Texas Radiotherapy, Kathlene Simmons, <u>KathleneSimmons@att.net</u>

Source: Texas Radiotherapy and Barrigel

